Sulfasalazine use while Breastfeeding
Drugs containing Sulfasalazine: Azulfidine, Sulfazine, Azulfidine EN-tabs
Medically reviewed on Oct 25, 2018
Sulfasalazine Levels and Effects while Breastfeeding
Summary of Use during Lactation
Sulfasalazine and its active metabolite mesalamine are poorly excreted into breastmilk. However, rather high levels of the mesalamine metabolite N-acetyl-5-ASA appear in breastmilk and its effects on breastfed infants are unknown. Another sulfasalazine metabolite, sulfapyridine, also appears in milk and infant serum and might cause hemolysis, especially in newborn infants and in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The time of greatest risk for hemolysis in fullterm newborns without G6PD deficiency might be as short as 8 days after birth. Bloody diarrhea has occurred in an infant whose mother was taking sulfasalazine and a few cases of diarrhea have been reported in infants exposed to mesalamine in breastmilk, although the rate is not high. Most experts consider mesalamine derivatives to be safe during breastfeeding. If sulfasalazine is required by the mother, it is not a reason to discontinue breastfeeding, but carefully observe breastfed infants for diarrhea. Other mesalamine derivatives that do not contain a sulfonamide are preferred.
Sulfasalazine is a chemical combination of sulfapyridine and mesalamine (5-aminosalicylic acid; 5-ASA) which is considered to be the active component. Sulfapyridine is metabolized to acetylated and glucuronidated metabolites. Mesalamine is metabolized to N-acetyl-5-ASA which is inactive in treating inflammatory bowel disease, but its possible effects on the breastfed infant are unknown.
Maternal Levels. Three women who were taking 500 mg of sulfasalazine 4 times daily had breastmilk samples analysed 1 week postpartum. The times of the samples in relation to the doses were not stated. Sulfasalazine milk levels averaged 2.7 mg/L, total sulfapyridine (including all metabolites) averaged 10.3 mg/L and free sulfapyridine (not including metabolites) was 6.5 mg/L. Mesalamine and its metabolites were not measured.
Twelve patients with inflammatory bowel disease were started on sulfasalazine 3 weeks postpartum and had breastmilk levels taken 2 to 3 weeks later. Of 31 samples in the 12 women, only 5 samples had detectable (>1 mg/L) sulfasalazine levels, ranging from 1.5 to 2.5 mg/L with dosages of 1 or 2 grams of sulfasalazine daily. Eight of the patients had 16 untimed milk levels measured while taking dosages of 1 to 3 grams daily. Milk sulfapyridine levels ranged from 1 to 38 mg/L, with some correlation to dosage. Almost no sulfapyridine metabolites were found in milk.
A woman began taking sulfasalazine 500 mg 4 times daily at 4.5 months postpartum for ulcerative colitis. She provided milk samples on 8 days over the next 2 months. A total of 44 samples were obtained, including 10 on the first day of medication. Other samples were obtained midway between nursing bouts which occurred about ever 4 hours. Sulfasalazine was not found in any of the milk samples. Sulfapyridine appeared in milk 4 hours after the first dose in a concentration of 4.8 mg/L. Over the next 2 weeks, sulfapyridine levels fluctuated in the range of 3.9 to 6.6 mg/L and acetylsulfapyridine levels were in the range of 0.4 to 2 mg/L. Total sulfapyridine plus metabolites were in the range of 3.2 to 13 mg/L with most values between 5 and 8 mg/L. Mesalamine was not detected in breastmilk.
Three women who were taking sulfasalazine 3 grams daily for ulcerative colitis each had a single milk level measured 3 to 4 days postpartum. Sampling time in relation to the dose was not reported. Sulfasalzaine levels ranged from <0.5 mg/L to 1.2 mg/L; sulfapyridine levels ranged from 9 to 16.9 mg/L; acetylsulfapyridine levels ranged from 1.1 to 6.7 mg/L. Mesalamine levels were uniformly 0.02 mg/L and N-acetyl-5ASA levels ranged from 1.2 to 3.4 mg/L.
Eight women were taking sulfasalazine during pregnancy and postpartum in an average dosage of 2.6 grams daily. Milk samples were taken 2 hours after breastfeeding, but times in relation to a dose were not stated. Sulfasalazine was undetectable (<0.5 to 1 mg/L) in all but one milk sample in which it was 4.1 mg/L. Sulfapyridine levels in 7 of the samples ranged from 12 to 60 mg/L.
Infant Levels. The breastfed infant of a mother taking sulfasalazine 500 mg 4 times daily had levels of sulfapyridine plus metabolites measured in urine 3 times during 2.5 months of therapy, beginning at 4.5 months postpartum. Total sulfapyridine plus metabolites ranged from 3 to 4.1 mg/L, with most of the drug appearing as metabolites. No mesalamine was detected in the infant's urine.
A 3-month-old breastfed infant whose mother was taking sulfasalazine 3 grams daily had a sulfapyridine blood level of 5.3 mg/L. The infant's mother was a slow acetylator, but the infant's acetylator status was not determined.
Eight breastfed infants whose mothers were taking sulfasalazine in an average dosage of 2.6 grams daily had serum levels measured once between 2 and 24 weeks of age. Sulfasalazine serum levels were undetectable (<0.5 to 1 mg/L) in 6 infants. In the other 2 infants, sulfasalazine serum levels were 1 and 1.7 mg/L. Sulfapyridine was detectable in 5 infants' serum in levels ranging from 1 to 4.8 mg/L.
Effects in Breastfed Infants
One group of investigators stated that they had 10 years of experience using sulfasalazine during the puerperium with no obvious adverse effects in breastfed infants.
The breastfed infant of a mother taking sulfasalazine 500 mg 4 times daily beginning at 4.5 months postpartum experienced no adverse effects during 2.5 months of nursing.
A 2-month-old breastfed infant whose mother was taking sulfasalazine 3 grams daily had an episode of bloody diarrhea. The bloody diarrhea recurred 2 weeks later and persisted until 3 months of age. The infant had up to 6 bowel movements daily and the stools had a loose consistency and were mixed with fresh blood. A colonoscopy revealed a mild inflammatory process and numerous punctate erosions in the mucosa. The infant had a sulfapyridine blood level of 5.3 mg/L, which may have been enhanced because the infant's mother was a slow acetylator. The bloody diarrhea stopped 48 to 72 hours after the mother stopped taking sulfasalazine. A repeat colonoscopy at 4.5 months of age was normal and no further bloody diarrhea occurred up to 14 months of follow-up. The authors felt that the reaction was likely caused by an allergic reaction to sulfapyridine. The reaction was probably caused by sulfasalazine or one of its metabolites in breastmilk. Both sulfapyridine and mesalamine have been reported to cause diarrhea in breastfed infants.
Eight infants whose mothers were taking sulfasalazine in average dosage of 2.6 grams daily were breastfed. Sulfapyridine was detectable in 5 infant's serum in levels ranging from 1 to 4.8 mg/L. The authors pointed out that these levels were far below those required to displace bilirubin from serum albumin binding sites.
A small controlled study reported only in abstract form found no higher rate of diarrhea in the breastfed infants of mothers taking mesalamine or sulfasalazine than in control infants.
A woman with Crohn's disease used sulfasalazine 4 g/day during pregnancy and postpartum. During breastfeeding (extent not stated) she also received infliximab 5 mg/kg every 8 weeks and prednisone 60 mg/day in a tapering schedule. At 6 months of age, the infant was asymptomatic with regular weight gain.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
1. Zao J, Koren G, Bozzo P. Using nitrofurantoin while breastfeeding a newborn. Can Fam Physician. 2014;60:539-40. PMID: 24925943
2. Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014;11:116-27. PMID: 23897285
3. Mahadevan U, Matro R. Care of the pregnant patient with inflammatory bowel disease. Obstet Gynecol. 2015;126:401-12. PMID: 26241432
4. Nguyen GC, Seow CH, Maxwell C et al. The Toronto Consensus Statements for the Management of IBD in Pregnancy. Gastroenterology. 2016;150:734-57. PMID: 26688268
5. van der Woude CJ, Ardizzone S, Bengtson MB et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107-24. PMID: 25602023
6. Flint J, Panchal S, Hurrell A et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016;55:1693-7. PMID: 26750124
7. Gotestam Skorpen C, Hoeltzenbein M, Tincani A et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795-810. PMID: 26888948
8. Azad Khan AK, Truelove SC. Placental and mammary transfer of sulphasalazine. Br Med J. 1979;2:1553. PMID: 43760
9. Jarnerot G, Into-Malmberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol. 1979;14:869-71. PMID: 44005
10. Berlin CM Jr, Yaffe SJ. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. Dev Pharmacol Ther. 1980;1:31-9. PMID: 6108198
11. Christensen LA, Rasmussen SN, Hansen SH et al. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid. Acta Obstet Gynecol Scand. 1987;66:433-5. PMID: 2892343
12. Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand. 1987;76:137-42. PMID: 2882643
13. Branski D, Kerem E, Gross-Kieselstein E et al. Bloody diarrhea--a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr. 1986;5:316-7. PMID: 2870147
14. Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet. 1989;333:383. Letter. PMID: 2563532
15. Follmer W. Uber die anwendung sulfonamiden im wochenbett. Klin Wochenschr. 1941;20:912-3.
16. Moretti ME, Spiczynski Y, Hashemi G et al. Prospective follow-up of infants exposed to 5-aminosalicylic acid containing drugs through maternal milk. J Clin Pharmacol. 1998;38 (Suppl):867. Abstract.
17. Correia LM, Bonilha DQ, Ramos JD et al. Inflammatory bowel disease and pregnancy: report of two cases treated with infliximab and a review of the literature. Eur J Gastroenterol Hepatol. 2010;22:1260-4. PMID: 20671559
CAS Registry Number
Anti-Inflammatory Agents, Non-Steroidal
LactMed Record Number
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about sulfasalazine
- Sulfasalazine Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 85 Reviews
- Drug class: 5-aminosalicylates
- Sulfasalazine Delayed-Release Tablets
- Sulfasalazine Tablets
- Sulfasalazine (Advanced Reading)